Beer Tomasz M, Venner Peter M, Ryan Christopher W, Petrylak Daniel P, Chatta Gurkamal, Dean Ruether J, Chi Kim N, Curd John G, DeLoughery Thomas G
Division of Hematology and Medical Oncology, Oregon Health and Science University, Portland, OR 97239, USA.
Br J Haematol. 2006 Nov;135(3):392-4. doi: 10.1111/j.1365-2141.2006.06322.x. Epub 2006 Sep 19.
The incidence of venous and arterial thrombosis in a placebo-controlled randomised trial of DN-101 (high dose calcitriol) with docetaxel versus docetaxel was compared. Of the 13 thrombotic events observed in the 250 patients enroled in this study, two occurred in DN-101 and 11 in placebo-treated patients (P = 0.01). This difference remained significant after adjustment for baseline history of thrombosis, atrial fibrillation and use of anti-thrombotic agents. In vitro and vitamin D receptor (VDR) knockout mouse studies predict that nanomolar concentrations of calcitriol may act as an antithrombotic agent. We report the first clinical observation that supports this hypothesis in humans.
在一项将多西他赛与DN-101（高剂量骨化三醇）进行对比的安慰剂对照随机试验中，对静脉和动脉血栓形成的发生率进行了比较。在这项研究纳入的250名患者中观察到13例血栓形成事件，其中2例发生在使用DN-101的患者中，11例发生在接受安慰剂治疗的患者中（P = 0.01）。在对血栓形成、心房颤动的基线病史以及抗血栓药物的使用情况进行校正后，这一差异仍然显著。体外研究以及维生素D受体（VDR）基因敲除小鼠研究预测，纳摩尔浓度的骨化三醇可能具有抗血栓形成作用。我们报告了首个在人体中支持这一假设的临床观察结果。
